FDA FOIA Monitor: Special Edition, 2015–2026 Baseline Report
foiadocs.com · Special Edition

FDA FOIA Monitor

2015–2026 Baseline Report

Updated 7/26/26: FDA posted the May and June 2026 open logs after this edition first published, revealing that a meaningful number of requests we'd counted as closed were still pending. The figures below have been revised accordingly. It changed the story in a few places, most notably processing times, which are faster across most doc types than we originally reported. See the June 2026 issue for how this affected that month specifically.

64,339 Closed FDA FOIA Requests.
Here Is What They Tell Us.

This special edition establishes the baseline: every FDA FOIA request on file from 2015 through June 2026, analyzed for volume trends, processing times, requester behavior, and document type patterns. 70,243 requests are on file in total; 5,904 remain pending and are not yet closed. The figures below reflect closed requests only unless noted. Bookmark it. Monthly issues will mark movement against this foundation.

64,339 Closed Requests (2015–2026)
70,243 on file · 5,904 still pending
72.9% Full Release Rate
Of closed requests; 1.4% formally denied
25 days Median Processing Time
Avg: 142 days (long tail of complex requests)
15,525 Unique Requesters
Individuals, firms, and orgs that have filed at least once
13,383 Peak Year: 2024
5,581 closed so far in 2026 (through June)
14.9% Withdrawal Rate
Of closed requests, most due to fees or data found elsewhere

Processing Times Are Rising. Fast.

Median close times have climbed steadily since 2024. The 2026 median across most doc types now sits at or above levels last seen in 2022.

FAERS
16 days
+7% vs '24
ANDA
██
24 days
+60% vs '24
483
██
22 days
+38% vs '24
EIR
███
37 days
↓ 10% vs '24
NDA
███
36.5 days
+83% vs '24
FSVP
█████████
106 days
+715% vs '24
Correspond.
████████
99 days
+230% vs '24
510(k)
█████████████████
203 days
↓ 3% vs '24
PMTA
█████████████████████████████████████████████████
611 days
+175% vs '24

Bar length (in block characters) proportional to 2026 median, scaled to PMTA's 611-day median. Green/gold/red text = fastest to slowest track.

Practitioner Takeaway If you have a time-sensitive FAERS, 483, or ANDA request, file now, those are still the fastest tracks at 16 to 24 days. FSVP has seen the steepest jump in the dataset, up 715% from 13 days (2024) to 106 days (2026). PMTA at 611 days remains essentially its own category.

Who Files FDA FOIA, and How They Do It

Of the 70,243 requests on file, commercial FOIA services dominate volume at 31.2% of all filings, ahead of individual/citizen requesters at 27.7%. The most striking trend is still news media: outlets grew requests 226% from 2020 to 2025 (313 to 1,019), including 147% growth in 2024 alone (494 to 1,218).

Category Total % of All Median Days Release Rate
Commercial FOIA Services
Redica Systems · Fdazilla · Registrar Corp
21,609 31.2% 22 84.3%
Individual / Citizen 19,159 27.7% 28 65.7%
Regulated Industry 15,480 22.4% 25 70.5%
Law Firms 5,760 8.3% 36 65.4%
News / Media
Capitol Forum · Bloomberg · Daily Signal
4,678 6.8% 29 64.7%
Academic / Research 1,869 2.7% 26 70.5%
Advocacy / NGO 543 0.8% 36 69.1%
Government 81 0.1% 4 34.7%
Key Finding Commercial FOIA services now have the highest release rate in the dataset at 84.3%, and file in a median of 22 days, the fastest track of any requester type. Government requesters (GAO, federal defenders, congressional offices) file least often and now show the lowest release rate at 34.7%, a meaningful shift from what earlier, pending-inflated figures suggested. Bloomberg and Capitol Forum continue to drive most of the News/Media growth.

544 GLP-1 Requests Closed Since 2020. 2024 Remains the Peak Year.

GLP-1 FOIA requests grew steadily from 2020 through the 2024 peak, then eased in 2025 as some of that year's filings remain in the pending queue rather than closed. 2026 volume is running below 2024's pace so far, though a portion of this year's requests are also still open. Of the 544 total, 380 (54%) have been fully released. FAERS reports are the single most-requested doc type (217), followed by agency correspondence (98), NDA review files (76), and ANDA files (44).

2020
3
2021
10
2022
6
2023
██████
42
2024
████████████████████████████████████████
278
2025
█████████████████
115
2026 YTD
█████████████
87

Bar length (in block characters) proportional to count, scaled to 2024's peak of 278. Figures reflect requests closed in each calendar year. A meaningful share of 2025- and 2026-filed GLP-1 requests remain pending and will show up in later years' totals as they close.

Notable: Bloomberg's 2024 request for GLP-1 drug communications with food and beverage companies (closed after 705 days with "No Records") signals investigative appetite for supply chain and commercial angle. The Hunterbrook Media request on BLP Labs compounding enforcement released after 695 days.

Top 20 Most-Referenced Companies & Products/Topics

Companies are counted from the Company field (populated on about 25% of requests). Products/topics are counted from a text search of the Title field. Several names overlap both lists: Catalent, Eli Lilly, Novo Nordisk, Aurobindo, and a few others show up as both a company and a search topic.

TOP 20 COMPANIES

1
63
2
56
3
50
6
45
8
Merck
43
11
39
12
Catalent Indiana LLC
37
13
Abbott Nutrition
37
15
GlaxoSmithKline
33
16
30
17
30
18
AstraZeneca
29
19
General Mills
24
20
Sun Pharmaceutical Industries
2

TOP 20 PRODUCTS / TOPICS

1
Catalent
298
2
Syfovre (pegcetacoplan)
295
3
Eli Lilly
197
4
Novo Nordisk
178
5
Izervay (avacincaptad pegol)
167
6
Aurobindo (generics)
142
7
Sun Pharma (generics)
132
9
Abbott Laboratories
83
10
Allergan (botox & aesthetics)
81
11
CSL Plasma Inc.
75
12
Congressional Communications
73
13
Ivermectin (COVID-era)
61
14
AstraZeneca (oncology)
59
15
Essure (Bayer)
57
16
Janssen COVID-19 Vaccine
56
17
Novo Nordisk Inc.
41
19
General Mills Company
27
20
GVK Biosciences
2
What the rankings reveal Catalent (298) and Syfovre (295) top the Title-search list, with Catalent's count driven by ongoing CMO/enforcement scrutiny rather than a single event. Novo Nordisk shows up split across "Novo Nordisk" (178) and "Novo Nordisk Inc." (41), worth merging into one entry next time the search terms are cleaned up. Sun Pharmaceutical Industries is a good example of the Company-field gap: only 2 requests name it as the Company, but 132 requests reference it in the Title.

Watch List: Products With Significant FOIA Activity

Product / Term Category First FOIA Yr All Time 2024 2026 YTD
semaglutide GLP-1 2021 263 159 28
Syfovre Ophthalmology 2023 295 116 2
Catalent CMO / Enforcement 2020 298 39 36
Izervay Ophthalmology 2023 167 108 2
JUUL Tobacco / E-Cig 2020 99 13 2
Capricor Cell Therapy / Rare 2025 13 0 2
ivermectin Policy / COVID-era 2020 61 11 1
naloxone Opioid / OTC 2020 44 9 2

Product Tracker pulls from Title column (Sheet1, col L). Subscriber access includes live spreadsheet with formula-based tracking. Add any term to auto-populate counts.

Request Volume by Year

2020
███████████████████████████
9,098
2021
██████████████████████████
8,816
2022
███████████████████████████
8,914
2023
███████████████████████████████
10,480
2024
████████████████████████████████████████
13,383
2025
██████████████████████████████████
11,516
2026 YTD
Through June only, not on the same full-year scale as above
5,581

Bar length (in block characters) proportional to count, scaled to 2024's peak of 13,383. 2026 YTD (5,581 closed through June) is a partial year and shown without a bar; 5,904 more requests across all years remain pending.

A Baseline, Not a Snapshot

This special edition is meant to be evergreen: the full historical picture behind the FDA FOIA Monitor, not a single month's numbers. New subscribers can start here to understand the shape of the dataset before reading a monthly issue.

Monthly issues of the FDA FOIA Monitor track what changed since last month, processing time swings, emerging products and companies, and notable newly-released documents, against this baseline. See the latest monthly issue.
Back to blog